What If Men Got Hot Flashes? The Real Science Behind Menopause Symptoms (and Alloy's Approach to Treating Them)

The Question That Exposes a Real Inequity

Hot flashes are not a minor inconvenience. They are a neurological event driven by estrogen withdrawal, and they affect roughly 80% of women going through menopause. Ask most women who have experienced a severe one and they will describe drenching sweats, a heart rate spike, and a wave of heat that starts in the chest and radiates outward, sometimes leaving a residual chill that makes sleep impossible.

Now ask: if men experienced these symptoms at the same rate, with the same frequency and intensity, would medical research look different? Would treatment be faster, better-funded, and more aggressively prescribed?

That question is not a rhetorical flourish. It points to a documented gap. Menopause research was historically thin and under-resourced, and women were simultaneously told that hot flashes were "just part of aging." The data tell a different story.

The WomanRx framework for evaluating menopause care asks three questions: What does the physiology actually show? What does the evidence say about treatment? And where does a specific platform or approach, like Alloy Health, fit for a woman at her particular life stage? This article works through all three.

What Actually Causes a Hot Flash

A hot flash is a vasomotor symptom (VMS). It is not caused by rising body temperature. Your core temperature stays the same. What changes is the thermoregulatory set-point in the hypothalamus, specifically a narrowing of the "thermoneutral zone," the range within which your body does nothing to heat or cool itself.

Estrogen decline destabilizes this zone. Research published in 2022 in Menopause confirmed that KNDy neurons in the hypothalamic arcuate nucleus, specifically the ones releasing kisspeptin, neurokinin B, and dynorphin, are the central mediators. Neurokinin B rises sharply as estrogen falls, triggering the heat-dissipation response: peripheral vasodilation, flushing, and sweating.

Why Women's Thermoregulation Is Different From Men's

Men do experience thermoregulatory changes. Cancer survivors on androgen-deprivation therapy (ADT) for prostate cancer develop hot flashes in up to 80% of cases. This is one of the most direct windows we have into what estrogen loss actually does to the hypothalamus, and it confirms the mechanism is real and physiologically significant regardless of sex assigned at birth.

But healthy men do not experience the sustained, years-long estrogen decline that defines perimenopause and menopause in women. The average woman's estrogen drops sharply over the menopausal transition and stays low indefinitely. Men's testosterone declines more gradually and incompletely. The comparison reveals a gap in research attention: ADT-induced hot flashes in men have been studied with considerable urgency. Menopause-related hot flashes, affecting a far larger population, received far less systematic attention for decades.

How Long Do Hot Flashes Actually Last?

The old clinical teaching was "a few years." The SWAN (Study of Women's Health Across the Nation) data, published in JAMA Internal Medicine in 2015, changed that. The median total VMS duration was 7.4 years. Women who started having hot flashes before their final menstrual period had the longest duration: a median of 11.8 years. Black women experienced VMS for a median of 10.1 years, significantly longer than white women (6.5 years), a disparity that reflects both biological differences and differential access to treatment.

The Treatment Gap: Why So Many Women Go Untreated

Fewer than 25% of women with moderate-to-severe VMS receive any treatment, according to a 2016 analysis in Menopause. This is not because treatment does not work. Systemic estrogen is the most effective intervention for VMS, with randomized trial data showing a 75-80% reduction in hot flash frequency compared to placebo in the Women's Health Initiative (WHI) trials.

The treatment gap has several causes.

The WHI Misinterpretation Problem

In 2002, the WHI stopped its estrogen-plus-progestin arm early, citing increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism. Headlines declared hormone therapy dangerous. Prescriptions plummeted. What the headlines missed: the study population had a mean age of 63, more than a decade past the typical menopause transition. Re-analysis of WHI data by age at initiation, published in JAMA in 2008, showed that women who began HRT within 10 years of menopause or before age 60 had a more favorable risk profile, including a reduction in all-cause mortality in some analyses.

The 2022 Hormone Therapy Position Statement of The Menopause Society (formerly NAMS) states directly: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS."

That is as close to a green light as clinical guidelines get. Yet most women never hear it.

Clinician Knowledge Gaps

A 2019 survey of ob-gyn residents published in Obstetrics & Gynecology found that fewer than 7% of residency programs offered any formal menopause training. Women are receiving menopause care from clinicians who, through no fault of their own, were never systematically taught how to provide it.

Fear of Breast Cancer Risk

This is the most common reason women decline HRT, and it deserves a specific and honest answer. The absolute risk increase for breast cancer with combined estrogen-progestogen therapy is approximately 8 extra cases per 10,000 women per year of use, per the 2019 Lancet collaborative analysis. For context: daily alcohol consumption increases breast cancer risk by a comparable or greater amount. Estrogen-only therapy (used only by women without a uterus) shows a more favorable profile, with some studies suggesting a possible risk reduction.

The risk is real, not zero, and you deserve to know the actual numbers, not reassurance.

Life-Stage Guide: Menopause Symptoms From Perimenopause Onward

Symptoms and treatment decisions change significantly depending on where you are in the transition.

Perimenopause (Typically Ages 40-51)

Perimenopause begins when menstrual cycles become irregular and estrogen levels start to fluctuate, sometimes wildly. Hot flashes can start years before the final menstrual period. You may also notice sleep disruption, mood changes, brain fog, and changes in cycle length.

Fertility is still possible in perimenopause. ACOG Practice Bulletin 141 confirms that ovulation can occur irregularly and that contraception remains necessary for women in perimenopause who do not want to become pregnant. Low-dose combined oral contraceptives, if not contraindicated, can suppress VMS and provide cycle control while also preventing unintended pregnancy.

Early Postmenopause (Within 10 Years of Final Period)

This is the window during which systemic HRT carries the most favorable benefit-risk ratio. The "timing hypothesis," now supported by the Kronos Early Estrogen Prevention Study (KEEPS), suggests that initiating estrogen early in the postmenopausal window may have cardiovascular-neutral or beneficial effects that are not seen when therapy begins late.

Women in this stage are the primary candidates for standard-dose systemic HRT: typically conjugated equine estrogen 0.625 mg/day or estradiol 1-2 mg/day orally, or estradiol patches delivering 0.05-0.1 mg/day.

Late Postmenopause or Age Over 60

Initiating systemic HRT de novo after age 60 or more than 10 years from menopause requires a more individualized conversation. The risk-benefit ratio shifts. Genitourinary syndrome of menopause (GSM) and sexual health concerns, however, are effectively treated with low-dose vaginal estrogen at any age without meaningful systemic absorption, and The Menopause Society states it can be used even in women with a history of breast cancer in consultation with their oncologist.

Pregnancy, Lactation, and Contraception: What You Must Know

Systemic hormone therapy is contraindicated in confirmed pregnancy. Estrogen and progestogens used in HRT formulations are not safe during pregnancy, particularly in the first trimester, and should not be initiated if there is any possibility of ongoing pregnancy.

Perimenopause and Pregnancy Risk

Because ovulation can still occur during perimenopause, any woman who has not had 12 consecutive months without a menstrual period should not assume she is infertile. ACOG confirms that women in perimenopause who are sexually active with a partner capable of causing pregnancy need reliable contraception. An FSH level alone is not a reliable marker of infertility in this transition.

Lactation

Standard systemic HRT is not typically prescribed in the postpartum period during active breastfeeding. Estrogen may suppress milk production. Postpartum women experiencing severe VMS (which can occur in the context of postpartum estrogen withdrawal) should discuss options with a clinician, including non-hormonal approaches such as low-dose paroxetine 7.5 mg (Brisdelle, the only FDA-approved non-hormonal VMS medication at that dose) or gabapentin, pending weaning.

Women With a History of Hormone-Sensitive Cancer

Systemic HRT is generally contraindicated in women with a personal history of estrogen-receptor-positive breast cancer. Vaginal estrogen at low doses remains an option many oncologists consider acceptable, but the decision requires direct discussion with both an oncologist and a menopause-informed clinician.

Alloy Health: What It Offers and Where It Fits

Alloy Health is a telehealth platform that specializes in menopause care for women. It is physician-founded and focuses on prescribing FDA-approved hormone therapies with clinician consultation rather than a one-size approach.

What Alloy Prescribes

Alloy's prescribing menu includes estradiol patches, oral estradiol, topical estradiol gel, vaginal estrogen products, and micronized progesterone (Prometrium) for women with a uterus. These are not compounded or untested formulations. They are FDA-approved bioidentical or conventional HRT products that are the same medications a hospital-based gynecologist would prescribe.

Micronized progesterone is the progestogen with the most favorable safety data for breast and cardiovascular risk. The E3N French cohort study, published in Breast Cancer Research and Treatment, found no statistically significant increase in breast cancer risk when estrogen was combined with micronized progesterone, compared to significant increases with synthetic progestins. That distinction matters.

What Alloy Does Not Do

Alloy does not prescribe testosterone for women (a common off-label use for HSDD in postmenopausal women), nor does it appear to offer tibolone, which is not FDA-approved in the US. It does not replace in-person mammography, pelvic examination, or Pap smear. Alloy is appropriate for women who already have a primary care provider for preventive screenings but who have not been able to access knowledgeable menopause care.

Who Is a Good Candidate for Alloy's Model

Alloy's telehealth model is well-suited to:

• Postmenopausal women under 60 with bothersome VMS and no major contraindications
• Women in perimenopause with moderate-to-severe hot flashes who need cycle evaluation and hormonal management
• Women who have had menopause dismissed or undertreated by a previous provider and want a clinician who specializes in this area
• Women in geographically underserved areas without access to a NAMS-certified menopause practitioner

Who Should Be Careful or Seek Additional Evaluation First

Alloy's model requires honest self-reporting, and some women need in-person evaluation before starting HRT. These include:

• Women with unexplained vaginal bleeding (must rule out endometrial pathology before starting estrogen)
• Women with a personal history of DVT, pulmonary embolism, or thrombophilia (transdermal estrogen carries lower VTE risk than oral, but the clinical picture still requires careful assessment)
• Women with a personal history of breast cancer or strong family history suggesting BRCA1/2 status, who may need genetic counseling alongside menopause management
• Women with poorly controlled hypertension, active liver disease, or recent cardiovascular event

Non-Hormonal Options: When HRT Is Not the Right Fit

For women who cannot or choose not to use HRT, the evidence-based non-hormonal options are more limited but real.

Fezolinetant (Veoza), approved by the FDA in May 2023, is a neurokinin 3 receptor antagonist that directly targets the KNDy neuron pathway. In the SKYLIGHT 1 and 2 trials, fezolinetant 45 mg/day reduced hot flash frequency by approximately 60% versus placebo at week 12. It carries no known estrogenic activity and is an option for women with hormone-sensitive cancers, subject to clinician review.

Low-dose paroxetine mesylate 7.5 mg (Brisdelle) is the only FDA-approved SSRI for VMS. Clinical trial data show a reduction of approximately 5 hot flashes per day versus approximately 3.9 for placebo, a modest but real effect. It is not appropriate for women taking tamoxifen (a CYP2D6 interaction reduces tamoxifen efficacy).

Cognitive behavioral therapy (CBT) for hot flashes, studied in the MENOS 2 trial, reduced the problem rating of hot flashes significantly compared to control, though not the frequency. It works by changing how women experience and respond to symptoms rather than reducing the underlying neurological event.

PCOS, Thyroid, and Other Female-Specific Contexts

Women with polycystic ovary syndrome (PCOS) enter perimenopause with a different hormonal baseline. Higher androgen levels and a history of irregular cycles can make the transition harder to time and harder to treat. Research published in Human Reproduction suggests that women with PCOS may experience menopause onset 2 years later on average but do not necessarily have a shorter or milder VMS course.

Postpartum thyroiditis affects approximately 5-10% of women in the first year after delivery and can cause symptoms that overlap with perimenopausal VMS: heat intolerance, palpitations, sleep disruption. Thyroid function should be assessed before attributing all such symptoms to menopause in women in their 30s and early 40s.

Women with premature ovarian insufficiency (POI), defined as loss of ovarian function before age 40, experience all of the same VMS but with the added urgency of bone and cardiovascular protection, since low estrogen for a longer cumulative duration carries greater long-term risk. The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends hormone therapy at least until the average age of natural menopause (51) unless contraindicated.

What the Evidence Gap Means for You Personally

Women have been under-represented in cardiovascular trials, pharmacokinetic studies, and drug safety trials for decades. A 2020 analysis in JAMA Network Open found that women represented fewer than 38% of cardiovascular drug trial participants despite bearing a substantial disease burden.

In menopause research specifically, much of what we know about HRT safety comes from the WHI, a single large trial with significant limitations in generalizability, particularly to younger, symptomatic women. The KEEPS trial, the ELITE (Early versus Late Intervention Trial with Estradiol) study, and the Danish Osteoporosis Prevention Study have added nuance, but the dataset is still smaller than it should be.

"The evidence base for menopause management is not as strong as for many other areas of women's health, not because the questions are less important, but because they were asked later and funded less," as WomanRx clinical reviewer Rachel Goldberg, MD, notes in reviewing this article. "Women deserve to know that distinction when making decisions about their own care."

When a clinician or a platform tells you the evidence supports a recommendation, ask which population the evidence comes from. The honest answer is that it mostly comes from women over 60 in the WHI era, with more recent, more applicable data accumulating in trials that better represent the woman in perimenopause or early postmenopause. That nuance matters.

Practical Steps: Starting Menopause Care Through a Telehealth Platform

If you are considering Alloy or any telehealth menopause service, the following checklist helps you prepare.

Before your first visit:

• Record your last menstrual period date and cycle history for the past 6-12 months
• List all current medications, including antidepressants, anticoagulants, and tamoxifen, which all interact with HRT options
• Know your mammography status (current screening is generally required before initiating systemic estrogen)
• Have your blood pressure and BMI available
• Note any personal or first-degree family history of breast cancer, DVT, stroke, or endometrial cancer

Questions to ask your telehealth clinician:

• Which formulation (oral, patch, gel, ring) is best for my specific risk profile?
• Do I need progestogen, and if so, would micronized progesterone (Prometrium) be appropriate?
• How will we monitor my response and adjust the dose?
• What are my contraception needs if I am still in perimenopause?
• At what point would you refer me to an in-person specialist?

A starting dose of estradiol 0.05 mg/day transdermal patch is common for systemic VMS treatment, with titration based on symptom response at 8-12 weeks. Expect 4-6 weeks before meaningful symptom reduction. If you have a uterus and are using systemic estrogen, you need a progestogen, full stop, to protect your endometrium.